Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate.
作者信息
Giuliani Jacopo, Bonetti Andrea
机构信息
Department of Oncology, Mater Salutis Hospital-ASL 21 della Regione Veneto, Legnago (VR), Italy.
出版信息
Chin J Cancer Res. 2013 Oct;25(5):486-7. doi: 10.3978/j.issn.1000-9604.2013.10.13.
Abstract
摘要
相似文献
1
Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate.甲磺酸伊马替尼引入前后的胃肠道间质瘤和第二原发性恶性肿瘤
Chin J Cancer Res. 2013 Oct;25(5):486-7. doi: 10.3978/j.issn.1000-9604.2013.10.13.
2
Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: a systematic review.手术和甲磺酸伊马替尼治疗晚期胃肠道间质瘤的疗效：一项系统评价
Tumori. 2010 May-Jun;96(3):392-9. doi: 10.1177/030089161009600303.
3
Pathological complete response in advanced gastric stromal tumor after imatinib mesylate therapy: a case report.甲磺酸伊马替尼治疗晚期胃间质瘤后的病理完全缓解：一例报告
J Med Case Rep. 2011 May 21;5:197. doi: 10.1186/1752-1947-5-197.
4
Advanced gastrointestinal stromal tumors successfully treated with imatinib mesylate: a report of two cases.甲磺酸伊马替尼成功治疗晚期胃肠道间质瘤：两例报告
J Natl Med Assoc. 2003 Dec;95(12):1208-10.
5
Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment.晚期胃肠道间质瘤（GIST）患者在甲磺酸伊马替尼治疗期间的基因变化。
Langenbecks Arch Surg. 2006 Nov;391(6):615-21. doi: 10.1007/s00423-006-0103-z. Epub 2006 Oct 6.
6
Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy.前瞻性观察性研究伊马替尼治疗晚期胃肠间质瘤的日本患者：长期随访和第二恶性肿瘤。
Jpn J Clin Oncol. 2012 Jul;42(7):578-85. doi: 10.1093/jjco/hys056. Epub 2012 Apr 21.
7
Gastrointestinal stromal tumor (GIST) and imatinib.胃肠道间质瘤（GIST）与伊马替尼
Int J Clin Oncol. 2006 Jun;11(3):184-9. doi: 10.1007/s10147-006-0579-0.
8
ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.ACRIN 6665/RTOG 0132 期临床试验：新辅助甲磺酸伊马替尼治疗可切除的恶性胃肠道间质瘤：18F-FDG PET 监测及其与基因型和 GLUT4 表达的相关性。
J Nucl Med. 2012 Apr;53(4):567-74. doi: 10.2967/jnumed.111.094425. Epub 2012 Mar 1.
9
Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.甲磺酸伊马替尼与AKT抑制剂联合使用在胃肠道间质瘤临床前研究中具有协同作用。
Clin Cancer Res. 2017 Jan 1;23(1):171-180. doi: 10.1158/1078-0432.CCR-16-0529. Epub 2016 Jul 1.
10
Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.胃肠道间质瘤的基因表达谱和对甲磺酸伊马替尼的反应。
Mol Cancer Ther. 2009 Aug;8(8):2172-82. doi: 10.1158/1535-7163.MCT-09-0193. Epub 2009 Aug 11.
引用本文的文献
1
Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive-resistant differentiated thyroid cancer.多激酶抑制剂/仑伐替尼在同时性/异时性合并放射性抵抗分化型甲状腺癌的癌症患者中的应用。
Cancer Med. 2022 Oct;11 Suppl 1(Suppl 1):26-32. doi: 10.1002/cam4.5107.
2
Significance of Primary Malignant Tumors on the Outcome of Patients With Resected Gastrointestinal Stromal Tumors.原发恶性肿瘤对胃肠道间质瘤患者术后生存的意义。
In Vivo. 2020 May-Jun;34(3):1201-1205. doi: 10.21873/invivo.11893.
3
Frequency, localization, and types of gastrointestinal stromal tumor-associated neoplasia.胃肠道间质瘤相关肿瘤的发生频率、定位和类型。
World J Gastroenterol. 2019 Aug 14;25(30):4261-4277. doi: 10.3748/wjg.v25.i30.4261.
4
The Occurrence of Gastrointestinal Stromal Tumors and Second Malignancies.胃肠道间质瘤与第二原发性恶性肿瘤的发生
J Gastrointest Cancer. 2015 Dec;46(4):408-12. doi: 10.1007/s12029-015-9759-3.
5
Criminal or bystander: imatinib and second primary malignancy in GIST patients.罪犯还是旁观者：伊马替尼与胃肠道间质瘤患者的第二原发性恶性肿瘤
Chin J Cancer Res. 2013 Oct;25(5):490-2. doi: 10.3978/j.issn.1000-9604.2013.10.15.
本文引用的文献
1
Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy.前瞻性观察性研究伊马替尼治疗晚期胃肠间质瘤的日本患者：长期随访和第二恶性肿瘤。
Jpn J Clin Oncol. 2012 Jul;42(7):578-85. doi: 10.1093/jjco/hys056. Epub 2012 Apr 21.
2
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.酪氨酸激酶抑制剂（TKI）治疗慢性髓性白血病（CML）和其他血液系统恶性肿瘤过程中出现的恶性肿瘤。
Blood. 2011 Oct 20;118(16):4353-8. doi: 10.1182/blood-2011-06-362889. Epub 2011 Aug 16.
3
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.甲磺酸伊马替尼治疗伴有 c-Kit 突变或扩增的转移性黑色素瘤患者的 II 期、开放标签、单臂试验。
J Clin Oncol. 2011 Jul 20;29(21):2904-9. doi: 10.1200/JCO.2010.33.9275. Epub 2011 Jun 20.
4
KIT as a therapeutic target in metastatic melanoma.KIT 作为转移性黑色素瘤的治疗靶点。
JAMA. 2011 Jun 8;305(22):2327-34. doi: 10.1001/jama.2011.746.
5
Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities.伊马替尼时代的转移性胃肠道间质瘤：生存率提高及社会经济生存差距的消除
Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2194-201. doi: 10.1158/1055-9965.EPI-08-0237.
6
Occurrence of other malignancies in patients with gastrointestinal stromal tumors.胃肠道间质瘤患者中其他恶性肿瘤的发生情况。
Semin Diagn Pathol. 2006 May;23(2):120-9. doi: 10.1053/j.semdp.2006.09.004.
7
Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors.胃肠道间质瘤等胃肠道间质肿瘤的当前发病率及治疗结果。
J Am Coll Surg. 2006 Apr;202(4):623-9. doi: 10.1016/j.jamcollsurg.2006.01.002.
8
Small gastrointestinal stromal tumor concomitant with early gastric cancer: a case report.小胃肠间质瘤合并早期胃癌：一例报告
World J Gastroenterol. 2006 Feb 7;12(5):815-7. doi: 10.3748/wjg.v12.i5.815.
9
Synchronous primary adenocarcinoma, mucosa-associated lymphoid tissue lymphoma and a stromal tumor in a Helicobacter pylori-infected stomach.幽门螺杆菌感染的胃中出现的同步原发性腺癌、黏膜相关淋巴组织淋巴瘤和间质瘤。
J Gastroenterol Hepatol. 2002 Sep;17(9):1033-6. doi: 10.1046/j.1440-1746.2002.02649.x.
10
ARG tyrosine kinase activity is inhibited by STI571.ARG酪氨酸激酶活性被STI571抑制。
Blood. 2001 Apr 15;97(8):2440-8. doi: 10.1182/blood.v97.8.2440.
Zotero 插件